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Abstract
Menaquinone-7 plays a significant role in cardiovascular and bone health. In 
recent times there is a growing interest in understanding the role of Menaquinone-7 
in health and diseases. Several population-based studies have reported specific 
health effects of the long-chain menaquinones, notably MK-7, MK-8, and MK-9. 
There are several epidemiological studies, clinical trials, along with in vivo and in 
vitro studies confirming the role of Menaquinone-7 in health and diseases. More 
recently, research group at Synergia Life Sciences has discovered a wider role for 
Menaquinone-7 in energy homeostasis (VO2max), peripheral neuropathy, muscle 
cramps and mitochondrial respiration not only through improvement of the elec-
tron transport but also the perfusion improving oxygen availability. In the current 
chapter, the authors have discussed the wider physiological role of Menaquinone-7 
highlighting the recent research with Menaquinone-7 in the areas of Muscle and 
Nerve Health.
Keywords: Menaquinone-7, muscle cramps, peripheral neuropathy, bone health, 
cardiovascular, insulin resistance, deficiency, catabolism, SXR, energy homeostasis
1. Introduction
Menaquinone-7 belongs to Vitamin K group. The two general categories of 
vitamin K are Phylloquinone (Vitamin K1) and Menaquinones, also referred as 
MK-n (clinical nomenclature Vitamin K2-n) having side chains with 4–12 prenyl 
units (MK-n where n stands for the number of isoprenoid units, MK-4 to MK-12) 9 
(Figure 1). Their physiological and patho- physiological roles are specific.
2. Biological activity of Menaquinone-7
Vitamin K was discovered by the Danish scientist, Henrik Dam, in the 1930s. 
Dam’s discovery was during his quest to understand chicken’s cholesterol metabo-
lism by feeding them a diet free of sterols and low in fat [1]. This reduced their 
intake of fat-soluble vitamin K, resulting in chickens developing large subcu-
taneous and intramuscular hemorrhages. This initial finding led to isolating, 
identifying, and characterizing the structure of vitamin K and its importance as 
an anti-haemorrhagic agent. Of the many metabolic processes related to vitamin 
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K deficiency, bleeding remains the potentially most serious generally known 
consequence. However, the role of vitamin K’s impact on osteoporosis and its 
inhibitory role in arterial calcification and vascular biology is now recognized 
in general populations. It is axiomatic that these metabolisms require vitamin 
K for γ-carboxylation and that this step is essential to their proper functioning. 
However, there are many other functions of vitamin K recently discovered that 
seem to be independent of its classical co-factor function. Vitamin K’s metabolic 
effects, e.g., ameliorating effect on peripheral neuropathy, cramps, autonomic 
nervous system, improving perfusion, etc., remain unexplained. Additionally, 
vitamin K also acts as a ligand for the receptor SXR, the steroid and xenobiotic 
sensing nuclear receptor (SXR), which is a transcriptional regulator of the cyto-
chrome P450 gene CYP3A4.
Over the years, the understanding of the vitamin K family has evolved, with the 
recognition of two primary forms of vitamin K- vitamin K1 (phylloquinone) and 
vitamin K2 (menaquinones). All K-vitamins have same function, but they exhibit 
differences in bioavailability and bioactivity. Vitamin K2, the main storage form in 
animals, has several subtypes, which differ in isoprenoid sidechain length. These 
vitamin K2 homologs are called menaquinones and are characterized by the number 
of isoprenoid residues in their side chains. Menaquinones are abbreviated as MK-n, 
where M stands for menaquinone, the K stands for vitamin K, and the n signifies 
the number of isoprenoid side chain residues. MK-4 and MK-7 are the two promi-
nent menaquinones in human nutrition. MK-7 and other long-chain menaquinones 
are different from MK-4 in that they are not produced by human tissue but are 
generated by bacteria in the gut. The available information suggests that a range of 
vitamin K2 analogues are present as a mixture in several foods, e.g., in sauerkraut, 
hard cheese, soft cheese and curd cheese [2]. These foods have a long history of 
consumption by humans as basic foods.
Figure 1. 
Chemical structures of various isoforms of Vitamin K. chemical structures of some K vitamins and 
metabolites. Nomenclature: Chemical name and IUPAC name and abbreviation in brackets: (I) 2-methyl1,4-
naphthoquinone (Menadione; K3), (II) 2-methyl3-phytyl-1,4-naphthoquinone (Phylloquinone; K1), (III) 
2-methyl-3-phytyl-1,4-naphthoquinone-2,3-epoxide (Phylloquinone epoxide; K1O), (IV) 2-methyl-3-
geranyl-geranyl1,4-naphthoquinone (Menaquinone-4; MK-4), (V) 2-methyl-3-farnesylgeranylgeranyl-1,4-
naphthoquinone (Menaquinone-7; MK-7).
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Diet (Natto and cheeses) rich in menaquinones (primarily MK-7) is safe and 
requires no systemic validation for toxicity. However, because of the role of vitamin 
K (K1 and K2) in blood coagulation and potential health benefits, there has been 
considerable effort to elucidate the mechanism of action of menaquinones, primar-
ily MK-7. There is no known toxicity associated with high doses (dietary or supple-
mental) of the phylloquinone (vitamin K1) or menaquinones (vitamin K2) forms of 
vitamin K. In several human studies, Natto food, known to contain MK-7, has been 
investigated for its health benefits.
3. Menaquinone-7 safety
The adverse effects of menaquinones, including Menaquinone-7 has been 
investigated in several animal and in vitro toxicity studies. Findings from animal 
studies for acute, chronic, and genotoxicity and in vitro studies for mutagenicity 
and carcinogenicity showed no significant risks associated with exposure to mena-
quinones [3]. The absence of adverse effects or death suggest that the minimum 
lethal dose of Menaquinone-7 is greater than 2000 mg/kg bw [4].
The European Union has permitted the use of Menaquinone-7 as a source 
of vitamin K for nutritional purposes in foodstuffs. The European Food Safety 
Authority (EFSA, 2008) [5] examined the safety of Menaquinone-7. The chemistry, 
nomenclature, dietary sources, intake levels, and pharmacokinetics of menaqui-
nones, and data of nonclinical toxicity and on clinical outcomes related to safety 
(adverse events) was extensively reviewed by US Pharmacopeia Convention [6] and 
by the Institute of Medicine (IOM, 2000). The report considers menaquinone as an 
active form of vitamin K [7].
4. Menaquinone-7 in diet
Schurgers et al. [2] have studied levels of Menaquinone-7 in many food products 
globally and found that the Menaquinone-7 levels are quite negligible in all the food 
products except Natto, a staple food in Eastern Japan which contains almost 998 
mcg of Menaquinone-7 per 100 gm of Natto. The investigators also found small 
amounts of Menaquinone-7 in natural cheese. Researchers at Synergia Life Sciences 
have undertaken a study where a number of Indian food products were exam-
ined for the levels of Menaquinone-7. The foods tested had particularly included 
fermented foods consumed by Indians at large. It was observed that the regularly 
consumed food including fermented foods lack in Menaquinone-7. So, it can be said 
that Menaquinone-7 is negligible in Indian diet.
The only rich source of Menaquinone-7 is Natto which contains early 900 mcg 
of Menaquinone-7 in 100 gm’s breakfast [2, 8] and different types of cheese [9] 
though in small amounts. The various common 18 varieties of Dutch cheeses and 
13 varieties of European cheeses contain approximately on an average 1.14 and 1.36 
mcg Menaquinone-7 per 100 gm of cheese respectively [9]. The hard cheese, soft 
cheese and curd cheese from Netherlands contains approximately 1.3, 0.5 and 0.3 
mcg Menaquinone-7 per 100 gm cheese respectively [2]. Processed cheese from 
Japan reported 0.3 mcg Menaquinone-7 per 100 gm cheese [10].
Serum concentrations of Menaquinone-7 are higher in frequent natto  
eaters. Natto is a popular breakfast item used more widely in win Eastern Japan, as 
compared to Western Japan. The study by Kaneki et al. reports an average serum 
Menaquinone-7 concentration of 5.26 ng/ml in Eastern Japanese women (Tokyo), 
1.22 ng/ml in the Western Japanese women (Hiroshima) and 0.37 ng/ml in British 
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women (London) [11]. The serum concentrations in British women are negligible 
since they do not consume Natto, but their diet may include cheese which contrib-
utes to the small amounts of Menaquinone-7 in their serum.
Globally speaking Menaquinone-7 is negligible in diet. It is true that 
many bacteria that populate microbiota of the human intestine synthesize 
Menaquinones. However, it is realized that in the small intestine bacterial growth 
availing Menaquinone-7 is limited by the rapid transit times. Most synthesis of 
Menaquinones occur in the large intestine. Shearer et al. [12] and Suttie et al. 
[13] have examined the evidence of the contribution of gut menaquinones and 
concluded that while they do contribute to the human nutrition but not signifi-
cantly. Karl JP et al. have shown that total Menaquinone (Menaquinone-4 to 
Menaquinone-13) concentration in human gut is highly variable. They measured 
total daily excretion of menaquinones in feces. The median total daily excre-
tion of menaquinones in feces was 850 nmol/d but was highly variable (Range: 
64–5358 nmol/day) [14].
5. Role of Menaquinone-7 in various diseases
5.1 Cardiovascular diseases
Geleijnse et al. [15] studied 4807 men and women of aged 55 yrs. for 10 years to 
assess the association of dietary intake of K1 and K2 with aortic calcification, CVD, 
and total mortality. They concluded that “When consuming daily 45 mcg dietary 
K2, you have: 50% reduction of arterial calcification, 50% reduction of cardiovas-
cular death, 25 % reduction of all-cause mortality as compared to low intake of 
dietary K2!”
Gast et al. [16] studied 16,057 women, aged 49–70 years and free of cardio-
vascular diseases (at baseline) for 8.1 ± 1.6 years. The intake of vitamin K1 was 
211.7 ± 100.3 mcg/d and of vitamin K2 intake was 29.1 ± 12.8 mcg/d. They con-
cluded that there is inverse association of vitamin K2 with CHD with reduction of 
9.1% per 10 mcg/day. They also found out that vitamin K1 is not related to CHD.
The publication of the above two epidemiological studies, viz. Geleijnse et al. 
and Gast et al. Study, has expanded interest the investigations of various beneficial 
health effects of Menaquinone-7.
5.2 Bone health
Knapen et al. [17] investigated the effects of low-dose Menaquinone-7 on bone 
health in healthy postmenopausal women. Menaquinone-7 intake significantly 
improved vitamin K status and decreased the age-related decline in Bone Mineral 
Content (BMC) and Bone Mineral Density (BMD) at the lumbar spine and femoral 
neck. In another placebo-controlled study, the authors investigated the effect of 
Menaquinone-7 on BMD and found out that Menaquinone-7 preserves trabecular 
bone structure at the tibia along with decrease in undercarboxylated osteocalcin 
(ucOC) [18]. In another clinical study Kanellakis et al. [19] assessed the effect 
of dairy products enriched with calcium, vitamin D3, and Menaquinone-7 on 
parameters of bone metabolism in postmenopausal women following a 12-month 
intervention. The study revealed more favorable changes in bone metabolism 
and bone mass indices for the Vitamin K2 supplemented groups. Van Summeran 
et al. [20] studied the effect of 45 mcg Menaquinone-7 on the circulating levels of 
undercarboxylated osteocalcin (ucOC) and carboxylated osteocalcin (cOC) along 
with Menaquinone-7 levels in healthy prepubertal children. They showed that the 
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levels of Menaquinone-7 increased with the supplementation of Menaquinone-7 as 
compared to baseline levels.
Spronk HMH et al. in 2003 conducted an in vivo study for assessing tissue spe-
cific utilization of Vitamin K2 which resulted in prevention of arterial calcification 
in warfarin-treated rats. It was shown that the utilization of Vitamin K2 was more 
efficient in the aorta as compared to other tissues [21].
In a study by Yamaguchi et al., the authors have shown the anabolic effect of 
Menaquinone-7 on bone tissue and osteoblastic MC3T3-E1 cells in vitro [22].  
Min Zhu et al. have shown that Menaquinone-7 has a stimulatory effect on bone 
tissue and osteoblastic SAOS-2 cells in vitro [23]. These studies suggest the role  
of Menaquinone-7 in osteoblastic bone formation. Recently, it has also been 
shown that Menaquinone-7 protects osteoblasts from oxidative stress and has 
beneficial effects on proliferation, differentiation, and mineralization of  
osteoblasts [24].
5.3 Insulin resistance
A decade-long study of 38,094 Dutch males and females aged 20–70 found that 
the quartile of participants who consumed the most dietary Vitamin K were 20% 
less likely to develop type 2 diabetes than the quartile with the lowest intake of 
Vitamin K [25]. Vitamin K2 is linked to lowered risk of developing type 2 diabetes 
and also a stronger relationship exists for Vitamin K2 intake. The risk of developing 
type 2 diabetes drops for every 10 mcg (0.01 mg) increase in Vitamin K2 intake. 
In this study participants with the highest intake of K2 consumed 250–360 mcg 
(0.25–0.36 mg)/day. Thus, higher intake of Vitamin K2 is linked to lower diabe-
tes risk.
In an attempt to better understand how Vitamin K2 improves insulin sensitiv-
ity, researchers from S. Korea studied 42 healthy male volunteers. Participants 
were either given 30 mg (30,000 mcg) of Vitamin K2 or a placebo each day for 
4 weeks. Vitamin K2 supplementation significantly increased insulin sensitivity 
and seemed to be related to increased carboxylation (activation) of osteocalcin. 
Researchers concluded that Vitamin K2 can help regulate glucose metabolism by 
activating osteocalcin, an endocrine hormone that increases insulin sensitivity in 
humans [26].
Research has shown that for elderly men Vitamin K slows the development of 
insulin resistance [27]. The researchers concluded that Vitamin K2 plays a poten-
tially beneficial role in reducing the progression of insulin resistance amongst 
elderly men.
6. Recent research
6.1 Energy homeostasis (VO2max)
In a recent randomized controlled trial, McFarlin et al. investigated the effects of 
dietary supplementation of Menaquinone-7 on cardiovascular responses to a graded 
cycle ergometer test. Menaquinone-7 supplementation was associated with a 12% 
increase in maximal cardiac output, with a trend toward an increase in heart-rate 
AUC. No significant changes occurred in stroke volume [28]. Figure 2 demonstrates 
that Menaquinone-7 treatment was associated with increased cardiac output, stroke 
volume, heart rate, and decreased blood lactate. Overall, these changes are consis-
tent with increase maximal cardiovascular performance with oral Menaquinone-7 
supplementation.
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6.2 Mitochondrial respiration
Synergia research group has identified Menaquinone-7’s pivotal role in mito-
chondrial ATP generation by acting as a mitochondrial electron transport carrier, 
thus participating in the energy cycle of the cell. In human cell experiments, it 
has been shown that the cells’ maximum capacity to generate energy, defined as 
the reserve energy, increases by 30–40% with Menaquinone-7, thus, identifying 
the role of Menaquinone-7 in redox cycle by transporting electrons in electron 
transport chain and also mitochondrial generation of ATP (Figure 3). This dual 
role of Menaquinone-7 is especially important to the aging geriatric population and 
athletes in their need of a greater oxygen supply for the oxidative phosphorylation.
In another in vitro study, Menaquinone-7 rescued mitochondrial defects in 
numerous conditions that affect mitochondrial function. Menaquinone-7 was also 
effective at improving systemic locomotion defects in fully developed adult pink1 
and parkin mutant flies. Menaquinone-7 did not affect mitochondrial remodeling 
Figure 2. 
To visualize the 5 outcome variables (heart rate, stroke volume, cardiac output, oxygen consumption, and blood 
lactate) on the same scale all data maximal response data after 8 weeks of treatment with either a vitamin 
K2 (red) or control (rice flour; blue) were normalized using a Log10 adjustment. Plotted values represent 
increments of a Log10 scale consuming a specific supplement.
Figure 3. 
Mitochondrial respiration: Test sequence in sea horse XF-96 platform.
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directly, but by increasing Electron Transfer Chain efficiency, it contributed to the 
proton motif force that facilitates ATP production. Menaquinone-7 may thus con-
stitute a promising compound to treat mitochondrial pathology, also in Parkinson’s 
disease (PD) patients suffering from Pink1 or Parkin deficiency [29]. A clinical 
study has been proposed to investigate the potential effects of Menaquinone-7 in 
genetically determined PD with mitochondrial dysfunction [30].
6.3 Anti-inflammatory
Chronic inflammation is considered an underlying pathology of many dis-
eases that remain poorly understood and treated. Several important chronic 
diseases with an inflammatory background have been associated with vitamin 
K deficiency. These include cystic fibrosis, inflammatory bowel disease, pan-
creatitis, chronic kidney disease and osteoporosis [31, 32]. Circulatory mark-
ers of low-grade inflammation such as tumor necrosis factor-alpha (TNF-α), 
interleukin-1 alpha (IL-1α), and interleukin-1 beta (IL-1β) positively correlate 
with endothelial damage, atheroma formation, cardiovascular disease, and 
aging. Menaquinone-7 can modulate immune and inflammatory reactions 
in the dose–response inhibition of TNF-α, IL-1α, and IL-1β gene expression 
and protein production [33]. These findings highlight the anti-inflammatory 
properties of Menaquinone-7, elucidating the anti-inflammatory mechanism of 
Menaquinone-7 and in establishing the potential biomarker targets in clinical 
testing of the role of Menaquinone-7 in cardiovascular health as well as other 
chronic degenerative conditions.
6.4 Muscle health
Vitamin K deficiency impacts neuromuscular and vascular function, thus 
affecting the physical functioning. Vitamin K has a function in promoting vascular 
smooth muscle differentiation [34]. As disabilities in patients are directly related to 
muscle strength and physical performance, therefore it is crucial to focus on muscle 
strength and performance rather than muscle mass [35].
Handgrip indicates muscle strength and is directly related to lower-extremity 
strength. Calf circumference indicates skeletal muscle mass and is associated with 
higher strength [36, 37]. A longitudinal cohort study conducted in community-
dwelling adults (n: 633, aged: 55–65 years) analyzed the association between vita-
min K status and physical functioning over 13 years. An association of low vitamin 
K status with lower handgrip strength, smaller calf circumference was observed. 
Low vitamin status in women indicated an existence of association of low vitamin 
status with poorer functional performance score [38].
Some observational studies conducted in sarcopenia patients showed an associa-
tion of high vitamin K status in plasma with muscle strength, large muscle mass, 
and high physical performance.
Thus, it was concluded that physical performance scores rather than muscle 
mass indicated the beneficial effect of vitamin K on muscle quality [35].
Systremma or leg cramps is a common and distressing problem characterized 
by involuntary, painful, sudden contractions of the skeletal muscles. It has affect-
ing 30% of people who are over sixty-year-of age and 50% of people over eighty 
years of age [39, 40]. Muscle cramps may occur in normal subjects during a strong 
voluntary contraction, sleep, sports or pregnancy but it can also occur due to several 
pathological conditions such as myopathies, neuropathies, motoneuron diseases, 
metabolic disorders, hydroelectrolyte imbalances or endocrine pathologies, cirrho-
sis of liver, in patients on dialysis or may be triggered by intake of certain drugs such 
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as diuretics, laxatives, beta2-agonists, cimetidine, and phenothiazines. Treatment 
of the underlying cause could successfully relieve this symptom [41, 42].
Diverse causes of muscle cramps has led to varied treatment modalities in 
clinical practice with varying degree of success in relieving the symptoms [43, 44]. 
These modalities include quinine Sulphate [45], calcium channel blockers [46], 
magnesium [47], gabapentin [48], botulinum toxin [49], phenytoin [50], Vit E [51], 
carisoprodol and orphenadrine [52]. Although quinine is the most used treatment 
modality in this condition [41], it is associated with several side effects like arrhyth-
mia, tinnitus, headache, nausea, tremor, hypotension, and gastrointestinal upset, 
and occasionally, potentially fatal hypersensitivity reactions and thrombocytopenia 
[40, 41]. Due to severe toxicity encountered, US FDA has banned over-the-counter 
quinine-based products used for leg cramps [41, 53, 54]. This has generated a need 
for alternative therapeutic agents.
A preliminary open labeled observational study conducted by Vaidya et al. 
showed that daily administration of 100 mcg of Menaquinone-7 for 3 months was 
associated with a reduction in the frequency, intensity, and duration of idiopathic 
muscle cramps [55]. Menaquinone-7 at a dose of 100 mcg /day for 3 months was 
found to be well tolerated and safe and resulted in therapeutic relief of muscle 
cramps (Figure 4).
A research done by Mehta and Vaidya showed that daily administration of 
vitamin K relieves muscle cramps and prevents its recurrence. Vitamin MK-7 has 
longer half-life which facilitates its further utilization as it stays in the body for a 
longer duration. Vitamin K is a safe prophylactic for muscle cramps. Vitamin K 
also improves the muscle strength evident by relief of fatigue. The inventors have 
discovered relief from cramps when sufficient dose of vitamin K was administered 
systematically daily once or more. The preferred range was 10 μg to 1000 μg per 
day, and the preferred vitamin K was vitamin MK-7 [56].
6.5 Nerve health
Peripheral neuropathy (PN) also known as distal symmetric neuropathy or 
sensorimotor neuropathy, is a common problem with multifactorial aetiologies. 
Diabetes mellitus is the most common etiology of PN. Neural signals from sensory 
receptors in the cellular pathway of the peripheral nervous system are damaged in 
PN. It is a neurological complication where the nerves carrying sensory neurons 
Figure 4. 
Decrease in mean severity of cramps as noted on VAS score in both the groups which were divided depending 
upon the frequency of cramps viz., cramps every day in group A and 2–3 cramps every week in group B.
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from different parts of the body to the central nervous system are denervated hence 
causing numbness, tingling, motor paralysis and gland or organ dysfunction. PN 
is a disease with vast spectrum, found in a variety of groups of populations, com-
monly observed in geriatrics, obese and diabetic population [57].
An epidemiological study conducted by Martyn et al. has stated the worldwide 
prevalence of PN to be around 2.4% which is considerably increasing to 8% in 
patients older than 55 years [58].
Indian population is susceptible to PN due to large population density, exposed 
to different adverse environments for a living [59]. Amongst diabetic Indian popu-
lation, prevalence of neuropathy has been 26–31% [60–62]. In an Indian epidemio-
logical survey conducted amongst about 40 million diabetics in India, at least 10.4 
million diabetics showed the symptoms of PN [63].
Some patients with neuropathy may experience extremely painful symptoms, 
whereas others may have objectively marked neurological deficit without signifi-
cant painful neurological symptoms [64].
A systematic review analyzing the data of several studies stated that painful 
diabetic PN occurs in about one in six people with diabetes, impairing the quality 
of life of people and increasing healthcare cost. Although guidelines have suggested 
several treatment related recommendations, but they are associated with adjuvant 
side effects [65]. The risk of developing PN increases with the duration of diabetes 
and deteriorating glycemic control [64].
Neuropathy is a devastating event in patients with myeloma. Prolonged treat-
ment of Multiple Myeloma (MM) related drugs leads to development of PN in 70% 
of patients [66]. Neuropathic events in such patients leads to dose reduction of 
the primary agents (Bortezomib, Thalidomide and Lenalidomide) or reduction in 
frequency of the therapy. This could further lead to discontinuation of therapy by 
some of the patients. Therefore, neuropathy in MM needs to be addressed.
The etiopathology of PN is poorly understood. Many factors, including dietary 
deficiencies, may contribute to the clinical manifestation of the condition [67].
The neurologic manifestations of folate deficiency overlap with those of vitamin 
B12 deficiency and include cognitive impairment, dementia, depression and com-
monly PN [64].
Myelopathy with or without an associated neuropathy is the commonly recog-
nized neurological manifestations of vitamin B12 deficiency [68]. Methyl cobala-
min is a vitamin B12 analogue, necessary for the maintenance of the nervous system 
[69]. The diagnosis of neuropathy due to B12 vitamin deficiency remains a real 
challenge for the clinician [70].
The etiology of diabetic neuropathy has been a debatable topic however, neu-
ropathy due to an inflammatory autoimmune condition that damages the myelin 
sheet of peripheral nerves and role of menaquinone-7 deficiency in alleviating this 
condition are considered as the evolving possibilities for diabetic neuropathy.
Vitamin K is considered to have a role in myelin synthesis and repair in central 
and peripheral nervous systems. Myelin is a sphingolipid, a group of complex lipids 
which are found in all mammalian cells as a major components of cell membranes, 
present particularly in high concentrations in cells of the central and peripheral 
nervous systems [71]. Certain sphingolipids found in the central and peripheral 
nervous systems have shown a high correlation with the tissue levels of vitamin K. 
Initially recognized for their structural role, sphingolipids are now considered as 
the key players in major cellular events such as proliferation, differentiation, senes-
cence, cell–cell interaction, and transformation [72]. Furthermore, several recent 
research have shown a corelation of alterations in sphingolipids metabolism with 
aging process [73] and neurodegenerative disorders such as Alzheimer’s disease 
(AD) and Parkinson’s disease [52, 74].
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Scientific legacy of Meir Lev’s group depicted the role for vitamin K in sphingo-
lipid metabolism in a report published in Nature in 1958 [75]. The report showed 
that Vitamin K serves as a growth factor for the rumen strain Bacteroides melanino-
genicus (also known as Fusiformis nigrescens), which was later found to be linked to 
cell membrane homeostasis. When Bacteroides melaninogenicus was cultured in a 
medium without vitamin K, cells grew as filaments (i.e., elongated cells), were more 
fragile when subjected to shaking with glass beads and tended to auto-agglutinate 
when placed in buffer. Growth of bacteria under such condition was also greatly 
affected. Vitamin K deficient cultures yielding around 80% lower bacteria weight 
than those grown from vitamin K replete conditions [76]. Two other reports also 
explained the role of vitamin K at the membrane level. The reports showed the 
essential requirement of vitamin K for sphingolipid synthesis. Recent published 
studies that confirm the modulation of brain sphingolipids by vitamin K nutritional 
status, underscore the potentially far-reaching effect of vitamin K in brain function 
given the key role of these lipids in cell-signaling functions.
In the nervous system, vitamin K activates the carboxylation and activation 
of Gla residues on GAS6 protein (growth arrest-specific gene 6 protein) which is 
structurally related to another vitamin K-dependent protein (VKDP), anticoagula-
tion factor protein S [77]. GAS6 and related S protein bind and activate the receptor 
tyrosine kinases of the Tyro3, Axl, and Mer (TAM) family. They are responsible for 
cell signaling which stimulates the generation of central nervous system repair cells 
(oligodendrocytes) and increased myelin production including repair after myelin 
injury (demyelinating injury) [78]. Vitamin K may also act in the central nervous 
system independent to its role in the carboxylation reaction [79]. Vitamin K inde-
pendent of VKDP, activates enzyme 3-ketodihydrosphingosine (3-KDS), involved 
in sphingolipid synthesis which is critical for healthy myelin [80].
Sakaue M et al. investigated the protective effects of different forms of Vitamin 
K (Vitamin K1 and Vitamin K2–4) in an in vitro experiment conducted in primary 
cultured neurons from cerebella of rat pups where methylmercury-induced the cell 
death. They also investigated its protective effect against GSH-depletion-induced cell 
death by employing two intracellular glutathione (GSH) reducers, L-buthionine sulf-
oximine (BSO) and diethyl maleate (DEM), in primary cultured neurons and human 
neuroblastoma IMR-32 cells. It was observed that all the forms of Vitamin K inhibited 
the death of the primary cultured neurons indicating that vitamin K forms have the 
potential to protect neurons against cytotoxic methylmercury and agents that deplete 
GSH, without increasing intracellular GSH levels [81]. Kenji Onodera et al. while 
examining the antinociceptive effects of Vitamin K2–4 in diabetic mice found that 
no significant difference exist between non-diabetic and diabetic mice in the Vitamin 
K2–4 induced changes in the nociceptive threshold. This indicated the therapeutic 
effectiveness of Vitamin K2–4 for treating painful diabetic neuropathy [82].
A serendipitous discovery by two researchers, Mehta and Vaidya is that 
Menaquinone-7 relieves idiopathic muscle cramps as well as symptoms of diabetic 
neuropathy. PCT/IN2008/000465, application further claims the safety of usage of 
Menaquinone-7 in the various novel conditions like neuropathy [56].
In an open labeled study conducted by Kulkarni et al., it was shown that 
Menaquinone-7 at a dose of 100 mcg twice a day for 8 weeks (Figure 5) was well 
tolerated and safe with a therapeutic activity for the symptoms of peripheral 
neuropathy [83].
Based on the results of these studies, the next study which is a follow-up study in 
a larger cohort (n = 100) was planned to address the peripheral neuropathy experi-
enced by patients. Menaquinone-7 capsules (100 mcg / capsule, twice a day) were 
given orally for 8 weeks and were followed up to 12 weeks. By twelfth week, the 
score was reduced in megaloblastic anemia as well as in diabetes mellitus groups to 
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1–2 (Figure 6). The decrease was statistically significant (P < 0.0001). The tingling 
and numbness had reduced significantly. There was a significant decrease in the 
weakness and fatigue [84].
Recently a double-blind placebo-controlled efficacy and safety study of 
Menaquinone-7 was conducted in 60 patients presenting with peripheral neuropathy 
and suffering from either vitamin B12 deficiency and/ or type 2 diabetes mellitus. 
Patients from both the groups’ i.e., Vitamin B12 deficiency and type 2 diabetes mellitus 
had overall VAS score of 9 at baseline. By the end of the twelfth week, patients who 
were receiving Menaquinone-7 showed statistically significant reduction in the VAS 
score in Vitamin B12 deficiency as well as in type 2 diabetes mellitus to 2; whereas the 
patients who were taking placebo in Vitamin B12 deficiency group had reduced to 8, 
and in type 2 diabetes mellitus group to 9. This study was again performed with same 
protocol along with estimation of serum Menaquinone-7 levels in serum in a small 
sample size. The VAS score showed an inverse relationship between Menaquinone-7 
levels and peripheral neuropathy symptoms (Figure 7) [85, 86].
Figure 5. 
Decrease in the intensity and severity of PN from baseline to 8th week as noted on VAS score in the groups a and 
B, where group A (severe) had a VAS score of 8–9 and group B (moderate) with a score of 6–8 at baseline.
Figure 6. 
Decrease in the intensity and severity of PN from baseline to 8th week as noted on VAS score in the groups VBD 
(Vitamin B12 deficiency) and T2DM (type 2 diabetes mellitus).
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Antineoplastic agents are the chemotherapy drugs used for cancer. 
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent 
side effects caused by antineoplastic agents having a prevalence ranging from 19% 
to over 85%. CIPN is a mostly sensory neuropathy and is associated with motor 
and autonomic changes of varying intensity and duration [87]. Chemotherapeutics 
induces toxicity in peripheral nervous system. Oxaliplatin, an antineoplastic agent 
damages the blood brain barrier (BBB). The possible mechanisms of BBB dam-
age may include proinflammatory cytokines, ROS, or other neurotransmitters, 
all of which are involved in the peripheral nervous system toxicity induced by 
chemotherapeutics [88, 89]. The study of Sanna et al. has shown a direct correla-
tion between structural changes in the central nervous system and chemotherapy-
induced neurotoxicity [90].
An open labeled observational study to evaluate the iatrogenic neuropathy and 
its amelioration using Menaquinone-7 in patients with Multiple Myeloma with drug 
induced PN suggests for the first time that Menaquinone-7 has an ameliorative poten-
tial for relief of iatrogenic PN in Multiple Myeloma patients. Menaquinone-7 reduces 
the symptoms of PN like tingling, numbness, burning sensation, pain, causalgia, 
wooly feeling, and cramps caused during treatment of MM, thus Menaquinone-7 is 
found to be useful in the treatment of PN caused due to the therapy of MM [91].
Multiple myeloma (MM) is a type of hematological cancer which is character-
ized by excessive production of malignant plasma cell clones in the bone marrow 
[92]. Incidence of iatrogenic PN has been observed in patients with MM who 
received chemotherapy. It is primarily of a sensory or sensorimotor nature, and the 
symptoms of tingling, numbness, burning sensation and pain are predominantly 
bilaterally symmetric [93]. Development of debilitating drug induced PN is one 
of the major challenges in the treatment of MM, affecting compliance leading to 
discontinuation of therapy or dose/drug modification [94]. Thus, there is a need 
of any modality that could reduce the severity and allows continuation of effective 
therapy in the clinical setting. This preliminary observational study is the first study 
revealing the potential of Menaquinone-7 in relieving the symptoms of iatrogenic 
PN in MM patients.
7. Conclusion
Menaquinone-7 appears promising in the areas of chronic degenerative condi-
tions such as bone health, cardiovascular, diabetes, energy metabolism, peripheral 
neuropathy, cramps etc. Newer research is ongoing to confirm its role in many other 
Figure 7. 
Average VAS score and serum Vitamin K2–7 levels (ng/ml) in Vitamin B12 deficiency group (A) and type 2 
diabetes mellitus group (B).
13
Menaquinone-7: Wide Ranging Physiological Relevance in Muscle and Nerve Health
DOI: http://dx.doi.org/10.5772/intechopen.99809
Author details
Dilip Mehta, Anselm de Souza and Shashank S. Jadhav*
Synergia Life Sciences Pvt. Ltd., Mumbai, India
*Address all correspondence to: shashank@viridisbiopharma.com
areas including immunity, cognition, cancer etc. With the recent discovery of its 
many biological functions, Menaquinone-7 is sometimes referred to as a multitask-
ing vitamin. Globally speaking Menaquinone-7 is negligible in diet consumed by the 
population all around the world except in small pockets leading to Menaquinone-7 
insufficiency. Either lack or deficiency of a given vitamin invites multiple patholo-
gies, some mild some severe, some experiential some silent, some acute some 
chronic. Until this knowledge is available to an individual, he is likely to consider 
multiple healing effects of a vitamin as panacea. Researchers have now realized that 
most of the global population is facing multiple severe morbidities due to lack of 
or inadequate levels of Menaquinone-7 in diet and supplementation. The “Next Big 
Thing” in medicine is Menaquinone-7 with what the science has revealed already. 
This vitamin will advance on an exponential curve.
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